210 related articles for article (PubMed ID: 24029727)
21. Phos-tau peptide immunization of amyloid-tg-mice reduced non-mutant phos-tau pathology, improved cognition and reduced amyloid plaques.
Benhamron S; Rozenstein-Tsalkovich L; Nitzan K; Abramsky O; Rosenmann H
Exp Neurol; 2018 May; 303():48-58. PubMed ID: 29432723
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies.
Rosenmann H
Curr Alzheimer Res; 2013 Mar; 10(3):217-28. PubMed ID: 23534533
[TBL] [Abstract][Full Text] [Related]
23. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
Ittner A; Bertz J; Suh LS; Stevens CH; Götz J; Ittner LM
J Neurochem; 2015 Jan; 132(1):135-45. PubMed ID: 25041093
[TBL] [Abstract][Full Text] [Related]
24. Active full-length DNA Aβ
Rosenberg RN; Fu M; Lambracht-Washington D
Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
[TBL] [Abstract][Full Text] [Related]
25. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
[TBL] [Abstract][Full Text] [Related]
26. Tau immunization: a cautionary tale?
Mably AJ; Kanmert D; Mc Donald JM; Liu W; Caldarone BJ; Lemere CA; O'Nuallain B; Kosik KS; Walsh DM
Neurobiol Aging; 2015 Mar; 36(3):1316-32. PubMed ID: 25619661
[TBL] [Abstract][Full Text] [Related]
27. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease.
Novak P; Schmidt R; Kontsekova E; Kovacech B; Smolek T; Katina S; Fialova L; Prcina M; Parrak V; Dal-Bianco P; Brunner M; Staffen W; Rainer M; Ondrus M; Ropele S; Smisek M; Sivak R; Zilka N; Winblad B; Novak M
Alzheimers Res Ther; 2018 Oct; 10(1):108. PubMed ID: 30355322
[TBL] [Abstract][Full Text] [Related]
28. A walk through tau therapeutic strategies.
Jadhav S; Avila J; Schöll M; Kovacs GG; Kövari E; Skrabana R; Evans LD; Kontsekova E; Malawska B; de Silva R; Buee L; Zilka N
Acta Neuropathol Commun; 2019 Feb; 7(1):22. PubMed ID: 30767766
[TBL] [Abstract][Full Text] [Related]
29. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.
Tarawneh R; Holtzman DM
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):144-59. PubMed ID: 19355934
[TBL] [Abstract][Full Text] [Related]
30. Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules.
Davtyan H; Zagorski K; Rajapaksha H; Hovakimyan A; Davtyan A; Petrushina I; Kazarian K; Cribbs DH; Petrovsky N; Agadjanyan MG; Ghochikyan A
Sci Rep; 2016 Jul; 6():28912. PubMed ID: 27363809
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
[TBL] [Abstract][Full Text] [Related]
32. Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches.
Rüb U; Stratmann K; Heinsen H; Seidel K; Bouzrou M; Korf HW
J Alzheimers Dis; 2017; 57(3):683-696. PubMed ID: 28269779
[TBL] [Abstract][Full Text] [Related]
33. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.
Lasagna-Reeves CA; Castillo-Carranza DL; Jackson GR; Kayed R
Curr Alzheimer Res; 2011 Sep; 8(6):659-65. PubMed ID: 21605039
[TBL] [Abstract][Full Text] [Related]
34. Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model.
Krishnamurthy PK; Deng Y; Sigurdsson EM
Front Psychiatry; 2011; 2():59. PubMed ID: 22025915
[TBL] [Abstract][Full Text] [Related]
35. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.
Chai X; Wu S; Murray TK; Kinley R; Cella CV; Sims H; Buckner N; Hanmer J; Davies P; O'Neill MJ; Hutton ML; Citron M
J Biol Chem; 2011 Sep; 286(39):34457-67. PubMed ID: 21841002
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapeutic approaches for Alzheimer's disease.
Wisniewski T; Goñi F
Neuron; 2015 Mar; 85(6):1162-76. PubMed ID: 25789753
[TBL] [Abstract][Full Text] [Related]
37. Current Status of Clinical Trials on Tau Immunotherapies.
Ji C; Sigurdsson EM
Drugs; 2021 Jul; 81(10):1135-1152. PubMed ID: 34101156
[TBL] [Abstract][Full Text] [Related]
38. Distinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake.
Funk KE; Mirbaha H; Jiang H; Holtzman DM; Diamond MI
J Biol Chem; 2015 Aug; 290(35):21652-62. PubMed ID: 26126828
[TBL] [Abstract][Full Text] [Related]
39. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model.
Nisbet RM; Van der Jeugd A; Leinenga G; Evans HT; Janowicz PW; Götz J
Brain; 2017 May; 140(5):1220-1230. PubMed ID: 28379300
[TBL] [Abstract][Full Text] [Related]
40. Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies.
Clavaguera F; Grueninger F; Tolnay M
Neuropharmacology; 2014 Jan; 76 Pt A():9-15. PubMed ID: 24050961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]